P.3.b.039 Relationship of stress, cannabis use and first psychotic episode

2013 ◽  
Vol 23 ◽  
pp. S452-S453
Author(s):  
M. Selakovic ◽  
D. Dikeos
2016 ◽  
Vol 26 ◽  
pp. S505
Author(s):  
N.I. Nunez ◽  
M. Zubia Martin ◽  
S. López Zurbano ◽  
I. Zorrilla Martínez ◽  
P. Lopez Peña ◽  
...  

2010 ◽  
Vol 25 ◽  
pp. 1642
Author(s):  
S. Alberich ◽  
S. Barbeito ◽  
M. Fernández ◽  
M. Karim Haidar ◽  
S. Ron ◽  
...  

2010 ◽  
Vol 117 (2-3) ◽  
pp. 448-449
Author(s):  
Yuliya Zaytseva ◽  
Nataliya Korsakova ◽  
Isaac Gurovich ◽  
Andreas Heinz ◽  
Michael Rapp

2007 ◽  
Vol 17 ◽  
pp. S576-S577
Author(s):  
E. Del Moral ◽  
A. Palomino ◽  
C. Matute ◽  
J. Palomo ◽  
S. ´ Alvarez de Eulate ◽  
...  

2020 ◽  
Vol 13 (12) ◽  
pp. e240088
Author(s):  
Peter M Haddad ◽  
Majid Al Abdulla ◽  
Javed Latoo ◽  
Yousaf Iqbal

A 30-year-old man with no significant previous or family psychiatric history became severely anxious about his health after a positive COVID-19 test. Physical symptoms of COVID-19 were mild, with no evidence of hypoxia or pneumonia, throughout his illness. He was admitted to a quarantine facility. He remained highly anxious, and 1 week later, he developed paranoid delusions and auditory hallucinations (his first psychotic episode). He was treated with lorazepam 1 mg four times a day, mirtazapine 30 mg nocte and risperidone 1 mg two times a day. His psychotic symptoms lasted 1 week. He stopped psychiatric medication after 4 weeks and had remained well when reviewed 3 months later. A Diagnostic and Statistical Manual of Mental Disorders fifth edition diagnosis of brief psychotic disorder with marked stressor (brief reactive psychosis) was made. Anxiety about his health and social isolation appeared the main aetiological factors but an inflammatory component cannot be excluded. The case highlights that first episode psychosis can be associated with mild COVID-19.


Sign in / Sign up

Export Citation Format

Share Document